World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access
Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc
Journal website http://www.wjon.org

Original Article

Volume 1, Number 5, October 2010, pages 187-193

Twelve Years of Experience in the Management of Testicular Germ Cell Tumors at a Referral Center in Portugal

Figures

Figure 1.
Figure 1. Age distribution considering both subgroups: STCGT and NSTCGT.
Figure 2.
Figure 2. Cumulative survival in both subgroups of TGCT.
Figure 3.
Figure 3. Cumulative survival in all initial stages.
Figure 4.
Figure 4. Cumulative survival according to risk score stratification.

Tables

Table 1. Clinical Symptoms at Diagnosis in STGCT and NSTGCT
 
SymptomsSTGCT (%)NSTGCT (%)
LocalizedTesticular atrophy01 (2.1%)
Swelling testis6 (18.7%)9 (19.1%)
Pain9 (28.1%)14 (29.8%)
Post traumatic pain01 (2.1%)
Breast enlargement04 (8.5%)
DisseminatedRight atrium thrombus01 (2.1%)
Gastro-intestinal02 (4.3%)
Retroperitoneal ganglionar1 (3.1%)8 (17.0%)
Lumbar pain2 (6.2%)5 (10.6%)
Bone pain1 (3.1%)2 (4.3%)
Central nervous system1 (3.1%)0
Leg swelling01 (2.1%)

 

Table 2. Histological Characteristics and Different Stages of Both TGCT Groups
 
TypeNo. of casesStage
IAIBISIIAIIBIICIIIAIIIBIIIC
Seminomas3211310230021
Nonseminomas4732134610108
Embryonal Carcinoma14212210033
Mature Teratoma1001000000
Imature Teratoma1000000010
Choriocarcinoma2000000011
Mixed tumors281110151054
Teratocarcinoma1000100000

 

Table 3. Risk Classification
 
Risk Classification
GoodIntermediatePoor
STGCTNSTGCTSTGCTNSTCGTNSTGCT
No residual disease2923141
Residual disease05155
Progression11021

 

Table 4. Global Treatment Modalities Applied in Different Stages of TGCT. CT – Chemotherapy, RT - Radiotherapy
 
StageSeminomatousNonseminomatous
CT: Chemotherapy; RT: Radiotherapy
CTRTTotal of patientsCTRTTotal of patients
IA1511113
IB3-32-2
IS82108113
IIA2-23-4
IIB3-36-6
IIC---1-1
IIIB2-210-10
IIIC1-18-8